Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients

Abstract

APT/PCs exhibit a wide and challenging spectrum of behaviour. Temozolomide is the first-line chemotherapy, and other oncological therapies are emerging. Treatment response continues to be difficult to predict with currently studied biomarkers.